Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“A widely metastatic melanoma patient.
BRAF V600E + PTEN alteration. We know this biology.
MAPK activation. PI3K/AKT escape.
A classic resistance model Poor outcomes are expected
Yet…
In this patient, we achieved a near-complete response at 3 months (see imaging below).
So the real question is: What would you do in this case? BRAF–MEK inhibition alone? Combination strategies? Or upfront immunotherapy?”
More posts featuring Ahmet Dirican.
